• Dzik, W. H. (2006). “The NHLBI Clinical Trials Network in transfusion medicine and hemostasis: an overview.” Journal of Clinical Apheresis; 21:57-59.
  • George, J. N; Woodson, R. D; Kiss, J. E; Kojouri, K.; Vesely, S. K (2006). “Rituximab therapy for thrombotic thrombocytopenic purpura: a proposed study of the Transfusion Medicine/Hemostasis Clinical Trials Network with a systematic review of rituximab therapy for immune-mediated disorders.” Journal of Clinical Apheresis; 21:49-56.
  • Journeycake, J; Brambilla D; Ragni M. (2005). “Central venous access device-related infections in hemophilia (abstract).” Blood; 106: 898A.
  • Konkle, B. A. and Nemo, G. J. (2005). "Defining effective therapies in transfusion medicine and hemostasis: new opportunities with the TMH Network." Transfusion; 45(9): 1404-6.
  • Segal, J. B. and Dzik, W. H. (2005). "Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures: an evidence-based review." Transfusion; 45(9): 1413-25.
  • Slichter, S. J. (2006). “Background, rationale, and design of a clinical trial to assess the effects of platelet dose on bleeding risk in thrombocytopenic patients.” Journal of Clinical Apheresis; 21:78-84.
  • Steiner, M. E; Key N.S; Levy J. H; (2005). "Activated recombinant factor VII in cardiac surgery." Current Opinion in Anaesthesiology; 18(1): 89-92.
  • Giulino, L.B.; Bussel J.B.; Neufeld, E.J.; Pediatric Immunology Committees of the TMH Clinical Trial Network; (2007). "Treatment with rituximab in benign and malignant hematologic disorders in children." Journal of Pediatrics; 150(4): 339-44.
  • Hiller, C.D.; Blumber, N; Glynn, S.A.; Ness, P.M.; NHLBI Working Group in Transfusion Recipient Epidemiology and Outcomes Research; (2008). "Transfusion recipient epidemiology and outcomes research: possibilities for the future." Transfusion; 48(8): 1530-7.
  • Ragni M.V.; Journeycake J.M.; Brambilla D.J.; (2008) "Tissue plasminogen activator to prevent central venous access device infections: a systematic review of central venous access catheter thrombosis, infection and thromboprophylaxis." Haemophilia; 14:30-38.
  • Slichter S.J.; Kaufman R.M.; Assmann S.F.; Brecher M.E.; Gernsheimer T.; Hillyer C.D.; McCullough J.; Strauss R.G.; and Triulzi D.; (2008) "Effects of Prophylactic Platelet (Plt) Dose on Transfusion (Tx) Outcomes (PLADO Trial)" Blood: 112:111.
  • Josephson C.; Sloan S.; Granger S.; et al. (2009) "Increased incidence of Grand 2 and higher bleeding in pediatric PLADO trial patients." Transfusion: 49:19A-20A.
  • Slichter S.J.; Kaufman R.M.; Assmann S.F.; et al; (2010). "Dose of prophylactic platelet transfusions and prevention of hemorrhage." New England Journal of Medicine: 362(7):600-13.
  • Slichter S.J.; Triulzi D.J.; Assmann S.F.; (2010) "Prophylactic platelet transfusions." New England Journal of Medicine: 362:2142.
  • Triulzi D.J.; Assmann S.; Strauss R.G.; et al. (2009) "Characteristics of transfused platelets do not affect bleeding outcomes in hypoproliferative thrombocytopenia." Blood: 114:14-14.
  • Steiner M.E.; Assmann S.F.; Levy J.H.; Marshall J.; Pulkrabek S.; Sloan S.R.; Triulzi D. J.; Stowell C.P.; (2010) "Addressing the question of the effect of RBC Storage on Clinical Outcomes: The Red Cell Storage Duration Study (RECESS) (Section 7)." Transfus. Apher. Sci. Aug; 43(1):107-16.
  • Lehmann H.P.; Dambita N.; Buchanan G.R.; Casella J.F.; (2011) "Decision modeling of disagreements: Pediatric Hematologists' Management of Idiopathic Thrombocytopenic Purpora." Medical Decision Making. Mar 14.

Click here to print this page

 © Transfusion Medicine/Hemostasis Network. All rights reserved